Browse hierarchy: [Cardiovascular (CV)](/submissions/CV) → [Subpart B — Cardiovascular Diagnostic Devices](/submissions/CV/subpart-b%E2%80%94cardiovascular-diagnostic-devices) → [21 CFR 870.1345](/submissions/CV/subpart-b%E2%80%94cardiovascular-diagnostic-devices/870.1345) → QFJ — Intravascular Bleed Monitor

# QFJ · Intravascular Bleed Monitor

_Cardiovascular · 21 CFR 870.1345 · Class 2_

**Canonical URL:** https://fda.innolitics.com/submissions/CV/subpart-b%E2%80%94cardiovascular-diagnostic-devices/QFJ

## Overview

- **Product Code:** QFJ
- **Device Name:** Intravascular Bleed Monitor
- **Regulation:** [21 CFR 870.1345](/submissions/CV/subpart-b%E2%80%94cardiovascular-diagnostic-devices/870.1345)
- **Device Class:** 2
- **Review Panel:** [Cardiovascular](/submissions/CV)

## Identification

An intravascular bleed monitor is a probe, catheter, or catheter introducer that measures changes in bioimpedance and uses an algorithm to detect or monitor progression of potential internal bleeding complications.

## Classification Rationale

Class II (special controls). The special controls for this device are:

## Special Controls

In combination with the general controls of the FD&C Act, the intravascular bleed monitor is subject to the following special controls:

- (1) In vivo animal performance testing must demonstrate that the device performs as intended under anticipated conditions of use and evaluate the following:
	- (i) Device performance characteristics;
	- Adverse effects, including gross necropsy and histopathology; and (ii)
	- (iii) Device usability, including device preparation, device handling, and user interface.
- (2) Non-clinical performance testing data must demonstrate that the device performs as intended under anticipated conditions of use. The following performance characteristics must be tested:
	- (i) Tensile testing of joints and materials;
	- Mechanical integrity testing: (ii)
	- (iii) Friction testing;
	- (iv) Flush testing:
	- (v) Air leakage and liquid leakage testing;
	- (vi) Latching and unlatching testing;
	- (vii) Kink and bend testing;
	- (viii) Insertion force testing;
	- Torque testing; (ix)
	- Corrosion testing; and (x)
	- (xi) Dimensional tolerance testing.
- (3) Performance data must support the sterility and pyrogenicity of the device components intended to be provided sterile.
- (4) Performance data must support the shelf life of the device by demonstrating continued sterility, package integrity, and device functionality over the identified shelf life.
- (5) The patient contacting components of the device must be demonstrated to be biocompatible.
- (6) Software verification, validation, and hazard analysis must be performed.
- (7) Performance data must demonstrate electromagnetic compatibility (EMC), electrical safety, thermal safety, and mechanical safety.
- (8) Human factors performance evaluation must demonstrate that the user can correctly use the device, based solely on reading the directions for use.
- (9) Labeling must include:
	- Instructions for use: (i)
	- (ii) A shelf life and storage conditions:
	- (iii) Compatible procedures:
	- (iv) A sizing table; and
	- Quantification of blood detected. (v)

*Classification.* Class II (special controls). The special controls for this device are:(1) In vivo animal performance testing must demonstrate that the device performs as intended under anticipated conditions of use and evaluate the following:
(i) Device performance characteristics;
(ii) Adverse effects, including gross necropsy and histopathology; and
(iii) Device usability, including device preparation, device handling, and user interface.
(2) Non-clinical performance testing data must demonstrate that the device performs as intended under anticipated conditions of use. The following performance characteristics must be tested:
(i) Tensile testing of joints and materials;
(ii) Mechanical integrity testing;
(iii) Friction testing;
(iv) Flush testing;
(v) Air leakage and liquid leakage testing;
(vi) Latching and unlatching testing;
(vii) Kink and bend testing;
(viii) Insertion force testing;
(ix) Torque testing;
(x) Corrosion testing; and
(xi) Dimensional tolerance testing.
(3) Performance data must support the sterility and pyrogenicity of the device components intended to be provided sterile.
(4) Performance data must support the shelf life of the device by demonstrating continued sterility, package integrity, and device functionality over the identified shelf life.
(5) The patient contacting components of the device must be demonstrated to be biocompatible.
(6) Software verification, validation, and hazard analysis must be performed.
(7) Performance data must demonstrate electromagnetic compatibility (EMC), electrical safety, thermal safety, and mechanical safety.
(8) Human factors performance evaluation must demonstrate that the user can correctly use the device, based solely on reading the directions for use.
(9) Labeling must include:
(i) Instructions for use;
(ii) A shelf life and storage conditions;
(iii) Compatible procedures;
(iv) A sizing table; and
(v) Quantification of blood detected.

## Recent Cleared Devices (2 of 2)

| Record | Device Name | Applicant | Decision Date | Decision |
| --- | --- | --- | --- | --- |
| [K230273](https://fda.innolitics.com/submissions/CV/subpart-b%E2%80%94cardiovascular-diagnostic-devices/QFJ/K230273.md) | Saranas Early Bird Bleed Monitoring System | Saranas, Inc. | May 25, 2023 | SESE |
| [DEN180021](https://fda.innolitics.com/submissions/CV/subpart-b%E2%80%94cardiovascular-diagnostic-devices/QFJ/DEN180021.md) | Early Bird Bleed Monitoring System | Saranas, Inc. | Mar 1, 2019 | DENG |

## Top Applicants

- Saranas, Inc. — 2 clearances

---

**Source:** [https://fda.innolitics.com/submissions/CV/subpart-b%E2%80%94cardiovascular-diagnostic-devices/QFJ](https://fda.innolitics.com/submissions/CV/subpart-b%E2%80%94cardiovascular-diagnostic-devices/QFJ)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com